The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from AbbVie Inc.
This edition of Medical Crossfire®, filmed in conjunction with the 2016 Pan Pacific Lymphoma Conference, is designed to provide a dynamic discussion of changing paradigms in the care of patients with chronic lymphocytic leukemia (CLL). The rapid emergence of targeted agents has displaced traditional chemotherapeutic regimens in many settings and has helped overcome unfavorable prognostic factors, such as the chromosome 17p deletion. Nevertheless, these new agents have unique characteristics and adverse-event profiles physicians need to familiarize themselves with in order to optimize therapy for their patients with CLL.
Our program chair, Susan O'Brien, MD, and our expert faculty, Bruce D. Cheson, MD; John G. Gribben, MD, DSc, FRCP, FRCPath; and Jennifer A. Woyach, MD, each present a brief, 10-minute overview of key topics in the management of patients with CLL, as well as future therapeutic strategies. Each presentation is followed by an extensive panel discussion and Q&A session led by Dr. O’Brien. Throughout the activity, interactive online questions are posed to participants to assess their knowledge and facilitate self-assessment.
Instructions For This Activity & Receiving Credit
This educational activity is directed toward medical oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists involved in the research and treatment of hematologic malignancies.
John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Barts Health NHS Trust
Barts and The London School of Medicine
Queen Mary University of London
London, England, United Kingdom
Disclosure: Grant/Research Support: Janssen Pharmaceuticals Inc, Pharmacyclics; Consultant: Roche Pharmaceuticals, Genentech, Celgene, AbbVie Inc, Janssen Pharmaceuticals Inc, Pharmacyclics.
Susan O’Brien, MD
Associate Director for Clinical Sciences
Chao Family Comprehensive Cancer Center
Sue and Ralph Stern Center for Clinical Trials & Research
Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, Irvine
Disclosure: Grant/Research Support: Acerta, TG Therapeutics, Regeneron, Gilead, Pharmacyclics, ProNAi; Consultant: Amgen, Celgene.
Jennifer A. Woyach, MD
Division of Hematology
Department of Internal Medicine
The Ohio State University
Disclosure: Grant/Research Support: Acerta Pharma, Karyopharm Therapeutics, MorphoSys AG.
It is the policy of the University of Nebraska Medical Center, Center for Continuing Education and PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, the University of Nebraska Medical Center, Center for Continuing Education and PER® require everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. The University of Nebraska Medical Center, Center for Continuing Education and PER® have implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the University of Nebraska Medical Center, Center for Continuing Education and Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018